Mountain View, Calif., (June 20, 2018) – Namocell announced today that it has signed an agreement with Tomy Digital Biology to distribute Namocell’s Namo Single Cell Dispenser in Japan.
Financial details of the agreement were not disclosed.
Namocell’s microfluidic-based cell platforms dispense single cells into a 96-well plate in less than a minute, the company said. The firm added that its cell cartridges simplify sterile sorting and eliminate the potential for system clogging.
“The Japanese market is in need of a high-performance and cost-effective single-cell dispensing and sorting instrument that is at the same time gentle to the cell and easy to use,” Tomy CEO and President Kenjiro Tominaga said in a statement.
In December 2016, Namocell partnered with researchers at Massachusetts General Hospital to research circulating tumor cells using the Namo Single Cell Dispenser platform.
Namocell is a leading provider of single cell sorting and dispensing platforms to advance single cell research and development. By combining flow cytometry, microfluidics and liquid dispensing technologies, Namocell’s single cell dispensers provide the fastest and easiest way to identify and isolate single cells, and enable users to accomplish single cell sorting and dispensing in one step in a way that is gentle to live cells. We serve researchers and scientists in a variety of applications, including single cell genomics, cell line development, CRISPR, cell therapy, monoclonal antibody development, rare cell isolation, and synthetic biology. Learn more at www.namocell.com.